1. In Vivo
  2. >>Business Strategy

bioMerieux Pushes Ahead in Genomics

BioMerieux's investment in Genome Therapeutics Corp. may be small by pharmaceutical standards, but it signals a significant commitment for an in vitro diagnostics company. The French maker of infectious disease tests and the Massachusetts genomics company are collaborating on the development of tests for infectious diseases for humans and industrial applications. The alliance is broadly reminiscent of the deal between Becton Dickinson and Millenium Predictive Medicine, although the focus is infectious diseases and the size of the investment is much smaller. Still, it signals the increasing importance of novel content to diagnostics companies looking for high-margin, highly proprietary markers to grow their businesses.

bioMerieux SA 's investment in Genome Therapeutics Corp. may be small by pharmaceutical standards, but it signals a significant commitment for an in vitro diagnostics company [See Deal]. The French maker of infectious disease tests and the Cambridge, MA-based genomics company are collaborating on the development of tests for infectious diseases for human and industrial applications.

BioMerieux is giving $6.2 million to Genome Therapeutics in the first year of the four-year collaboration, including a $3.75 million...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.